Ypsilon Therapeutics, a portfolio company of 82VS, Alloy’s venture studio, has been awarded $2.7 million in seed funding from ...
The smaller antibody formats such as single-chain fragment variables, nanobodies or other scaffolds that can reach hidden targets or act as intrabodies to target intracellular antigens must strike a ...
The DNA vaccine-derived protein antigen (3) is then degraded by proteosomes into intracellular peptides (4). The vaccine derived-peptide binds MHC class I molecules (5). Peptide antigen/MHC I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback